Catalog Advanced Search

Search by Categories
Search in Packages
Search by Format
Search by Type
Search by Date Range
Products are filtered by different dates, depending on the combination of live and on-demand components that they contain, and on whether any live components are over or not.
Start
End
Search by Keyword
Sort By
  • Overdose Fatality Reviews: A Data-Driven Collaboration (1.5 CME)

    Contains 4 Component(s), Includes Credits

    Earn 1.5 AMA PRA Category 1 Credit(s)™ while learning about the structure and process of overdose fatality reviews. from this conference recording from The ASAM 50th Annual Conference (2019).

    (1.5 CME) In this conference recording from the 2019 Annual Conference, you will learn:

    Overdose fatality reviews allow communities to examine and understand the circumstances surrounding fatal drug overdoses. Review teams can uncover the individual and population factors and characteristics of potential overdose victims. Knowing the who, what, when, where, and how of fatal overdoses provides a better sense of the strategies and coordination needed to prevent future overdoses and results in the better allocation of overdose prevention resources and services. This session will provide an overview of overdose fatality review and highlight successes and challenges in the field from local, state and tribal perspectives.  Funding and training and technical assistance opportunities through Bureau of Justice Assistance will be highlighted. There will be a panel of four individuals and the session will include funding and training opportunities from the Bureau of Justice Assistance, an overview of the structure and process of an overdose fatality review, a state level view of the OFR model and features in Wisconsin, and a local level view  in Prince George County Maryland.

    Tara L. Kunkel

    MSW

    Tara Kunkel is presently on detail to the Department of Justice, Bureau of Justice Assistance through an interagency agreement serving as a Senior Drug Policy Advisor.  Ms. Kunkel oversees BJA’s prescription drug monitoring program as well as the Comprehensive Opioid Abuse Program.  Ms. Kunkel graduated from Virginia Commonwealth University with a Masters in Social Work and received her BA in Psychology from the University of Virginia.

    ACCME Accredited with Commendation

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s).  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    ABPM Maintenance of Certification (MOC)

    The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 1.5 LLSA credits towards ABPM MOC Part II requirements.

    ABAM Transitional Maintenance of Certification (tMOC)

    This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Transitional Maintenance of Certification Program (tMOC) can apply a maximum of 1.5 AMA PRA Category 1 Credit(s)™ for completing this course.

    ABIM Maintenance of Certification (MOC)

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn 1.5 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

  • Up in Smoke: Igniting Recovery from Tobacco and e-Cigarettes (1.5 CME)

    Product not yet rated Contains 4 Component(s), Includes Credits

    Earn 1.5 PRA Category 1 Credit(s)™ while learning how to improve nicotine and tobacco research from this conference recording from The ASAM 50th Annual Conference (2019).

    1.5 CME In this conference recording from the 2019 Annual Conference, you will learn that:

    Historically, substance use disorder treatment centers have only offered limited-to-no treatment for tobacco dependence during their programs.  Over the last 30 years, significant gains have been made in behavioral management for tobacco dependence, FDA approval of 7 medications, development of outpatient and inpatient treatment protocols, and the establishment of tobacco-free hospitals and behavioral treatment centers.  In addition, tobacco price elasticity, increased public health knowledge of risks, restrictions in tobacco marketing, and clean, indoor-air laws have resulted in lower tobacco consumption in the general population.  However, these gains have not had enough impact to lower the rates of tobacco-related chronic health diseases in individuals with substance use disorders.  Tobacco use is the number one cause of death for people with alcoholism1 . Furthermore, there are potential threats to the advances already made, including the rapid acceptance of electronic nicotine delivery systems (ENDS) within the last 10 years and the decriminalization and/or legalization of recreational or medical of cannabis use in 30 states over the past two decades. The increasing awareness of tobacco-related, chronic disorders amongst both the public and medical professionals presents an opportune climate for improving the screening and treatment of tobacco dependence in patients receiving treatment for other addictions.  Four potential opportunities include:
     
    1) Dissemination of an increasing number of novel, evidenced-based protocols specifically for individuals with tobacco and co-occurring substance use disorders; 2)  Recognition by medical and behavioral health providers of patient satisfaction and improved outcomes when tobacco is addressed during addiction therapy; 3) Identification, training and collaboration of addiction specialists to advance this concept; and 4)  Awareness of the potential use of ENDS to intentionally deliver other drugs of abuse and need for education of patients and staff about impact of ENDS products on long-term recovery.   This workshop will offer best practices of current evidence-based protocols and provide tools for creating effective treatment options that can be applied in a variety of settings.  The participants will engage in small group, interactive exercises that will develop action plans for addressing tobacco-use disorders within their own treatment settings and on a national level.    Outline: Review important historical milestones in efforts to treat tobacco dependence in addiction settings Discuss potential threats for gains already made in the treatment of tobacco dependence over two decades Discuss potential opportunities and challenges to improve the treatment of tobacco dependence for recovering populations Each participant will be empowered to develop a personalized Strengths, Weakness, Opportunities and Threats (SWOT) analysis of their program during the workshop.

    Learning Objectives:

    Upon completion, participant will be able to:

    Develop 3 novel and effective strategies for improving nicotine and tobacco treatment research, reimbursement, and service delivery.

    Lori D. Karan

    MD, DFASAM, FACP

    Lori Karan, MD, DFASAM, FACP is Professor of Internal Medicine and Preventive Medicine and Director of the Addiction Medicine Fellowship at the Loma Linda University Medical School.   She works in the Substance Treatment and Recovery (STAR) program of the Loma Linda VA Healthcare System (LLVAHCS). During her internal medicine training, Dr. Karan repeatedly treated patients for the consequences of tobacco use.  She recognized that nicotine and tobacco use were often ignored during the treatment of other substance use disorders and that tobacco was the number one cause of death in recovering persons. 

    Dr. Karan guest-edited a seminal issue of the Journal of Substance Abuse Treatment entitled “Towards a Broader View of Recovery.”  These experiences set the foundation for Dr. Karan’s longstanding interest in in the similarities and differences between nicotine and other addictive drugs. Dr. Karan advocated for tobacco control, including befriending the Phillip Morris whistleblower scientists and putting forth stockholder’s proposals during  annual meetings of Phillip Morris, and RJ Reynolds. She received a NIDA Scientist Development Award where she researched the discriminative stimulus effects and neuroendocrine basis for the subjective effect of nicotine.

     Dr. Karan and John Rosecrans PhD co-chaired nine annual ASAM Nicotine Research Round tables and from this excitement originated the Society for Research on Nicotine and Tobacco. More recently Dr. Karan and Dr. Susan Blank authored the Nicotine and Tobacco chapter of the ASAM Criteria where they advocated for increased intensity of treatment for persons who had severe nicotine/tobacco use disorders, medical, and/or psychiatric co-morbidity. Dr. Karan was recruited to LLVAHCS by Dr. Linda Ferry, originator of Zyban.  Dr. Ferry and Dr. Karan continue to develop effective treatments for nicotine and tobacco use, especially in patients who have other substance use disorders. 1 Hurt RD et al.  “Mortality following inpatient addictions treatment.” JAMA 1996 Apr 10; 275(14):1097-1103.

    Laura Martin

    MD, FASAM

    Laura F. Martin, M.D. is an Associate Professor of Psychiatry at the University of Colorado School of Medicine.  She is a board certified psychiatrist and addiction medicine specialist.  She has been recognized as a member of the American College of Psychiatrists, a Fellow of the American Society of Addiction Medicine, and a Distinguished Fellow of the American Psychiatric Association.   Her professional roles include serving as the Medical Director of the Center for Dependence, Addiction and Rehabilitation (CeDAR), Program Director of the Addiction Medicine Fellowship at the University of Colorado School of Medicine, and as President of the Colorado Society of Addiction Medicine.  She regularly works with individuals with both substance use disorders and other behavioral health disorders to improve their physical and mental health and has published peer reviewed research and clinical reviews regarding this work. 

    Linda Hyder Ferry

    MD, MPH

    Chad D. Morris

    PhD

    Chad Morris, Ph.D. is a Professor of Psychiatry at the University of Colorado- School of Medicine, and Director of the Behavioral Health & Wellness Program. He is the principal investigator of many projects and studies exploring the effectiveness of organizational, psychosocial, and pharmacologic wellness and tobacco cessation strategies. As the Vice President of Spark Inspiration, Dr. Morris also offers corporate wellness solutions. He has worked with over 40 states to foster sustainable whole health and tobacco control initiatives for priority populations including persons with mental illnesses, addictions, and justice involved individuals. 

    ACCME Accredited with Commendation

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s).  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    ABPM Maintenance of Certification (MOC)

    The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 1.5 LLSA credits towards ABPM MOC Part II requirements.

    ABAM Transitional Maintenance of Certification (tMOC)

    This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Transitional Maintenance of Certification Program (tMOC) can apply a maximum of 1.5 AMA PRA Category 1 Credit(s)™ for completing this course.

    ABIM Maintenance of Certification (MOC)

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn 1.5 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

  • Expanding Access to Buprenorphine for Justice-Involved Individuals via Mobile Treatment (1.5 CME)

    Contains 4 Component(s), Includes Credits

    Earn 1.5 AMA PRA Category 1 Credit(s)™ while learning how to expand access to MAT for justice-involved individuals from this conference recording from The ASAM 50th Annual Conference (2019).

    (1.5 CME) In this conference recording from the 2019 Annual Conference, you will learn that:

    Opioid use disorder (OUD) is highly prevalent among justice-involved individuals.  Despite evidence that increasing access to medications for addiction treatment (MAT) decreases fatal overdoses after release from prison and jail, many barriers to expanding treatment for this population remain.  Most interventions to date have focused on expanding access to MAT inside the criminal justice system, which can work well for those serving longer sentences in prisons, but the high turnover in jails and pre-trial detention centers is not always amenable to starting MAT inside jail. 
     
    In this interactive panel discussion, we will describe the development of Project Connections to Re-Entry (PCARE), a novel treatment model to expand access to buprenorphine for justice-involved individuals.  Started in November 2017, PCARE is part of a network of low-threshold buprenorphine treatment site run by Behavioral Health Leadership Institute (BHLI).  PCARE provides access to low threshold MAT through a mobile van parked directly outside the Baltimore City Jail in partnership with Maryland Department of Public Safety and Correctional Services. Patients are referred by jail staff or can walk in from the street. The clinical team includes an experienced primary care physician who prescribes buprenorphine, a nurse, and a peer recovery coach. Once stabilized, patients are transitioned to longer-term treatment programs or primary care for buprenorphine maintenance.

    Between November 2017 and July 2018, 249 people approached the van, 127 of whom began treatment with buprenorphine-naloxone.  The majority of patients (94.4%) had previous criminal justice involvement, were unemployed (72.4%) and were living with family or friends (41.7%). Of those who began treatment, 67.7% returned for a second visit or more, and 29% percent were still involved in treatment after 30 days. This focus session will begin with brief overview of current literature regarding access to MAT in criminal justice settings.  The interdisciplinary panel, composed of the program director (a lawyer) and physicians, will then describe the process of developing this program, client characteristics and initial outcomes, and implications for expansion to other treatment settings.

    The panel will discuss successes and challenges in partnering with detention center staff and engaging vulnerable populations in care.  After the panel discussion, the group will break into small groups to discuss ways of expanding access to buprenorphine in their own settings.  There will be time at end for Q+A.   Proposed Timeline (in minutes): 0:00 �" 0:10 Brief review of literature related to MAT in criminal justice setting and mobile      treatment models 0:10 �" 0:55 Panel discussion of PCARE low-threshold buprenorphine model 0:55 �" 1:10 Breakout into small groups to discuss expanding treatment in their own settings 1:10 �" 1:30 Questions and Answers/Session Evaluation

    Learning Objectives:

    1.)  Describe current literature on MAT for justice-involved populations.

    2.)  Describe a model of low threshold buprenorphine treatment for justice-involved individuals

    3.)  Identify ways to partner with criminal-justice settings and expand access to MAT for justice-involved individuals in their own geographic area


    Megan Buresh

    MD

    Dr. Megan Buresh is an Assistant Professor of Medicine and Epidemiology at the Johns Hopkins University School of Medicine.  She is board certified in internal medicine and addiction medicine and certified as AAHIVM HIV Specialist.  She received a Bachelor of Arts in Biochemical Sciences from Harvard University (magna cum laude with highest honors in field), completed medical school at Johns Hopkins University School of Medicine and residency at Brigham and Women’s Hospital.  She is the Secretary of the Maryland-DC ASAM Chapter. She is medical director of the Johns Hopkins Bayview Inpatient Addiction Consult Service.  She also provides integrated buprenorphine treatment as part of her outpatient primary care practice.  She is lead physician for BHLI PCARE, a mobile buprenorphine clinic for patients being released from Baltimore City Jail.  Her research interests include public health and addiction, developing and evaluating models to expand office-based opioid treatment, and improving linkages between clinical addiction treatment and community organizations.  She is a co-investigator with the ALIVE study at the Johns Hopkins Bloomberg School of Public Health, where she is studying risk factors for opiate overdose and access to naloxone among persons who inject drugs.    

    ACCME Accredited with Commendation

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s).  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    ABPM Maintenance of Certification (MOC)

    The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 1.5 LLSA credits towards ABPM MOC Part II requirements.

    ABAM Transitional Maintenance of Certification (tMOC)

    This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Transitional Maintenance of Certification Program (tMOC) can apply a maximum of 1.5 AMA PRA Category 1 Credit(s)™ for completing this course.

    ABIM Maintenance of Certification (MOC)

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn 1.5 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

  • The World of Weird Withdrawal (1.5 CME)

    Contains 4 Component(s), Includes Credits

    Earn 1.5 AMA PRA Category 1 Credit(s)™ while learning how to recognize the toxic syndromes that result from strategies patients use to self-treat opioid withdrawal. from this conference recording from The ASAM 50th Annual Conference (2019).

    (1.5 CME) In this conference recording from the 2019 Annual Conference, you will learn that:


    With changing patterns of opioid use, a growing number of patients are at risk for experiencing opioid withdrawal. Due to convenient access to “pseudo-medical” information via social media and purchasing options on the Internet, patients may be using a variety of substances to “self-detox” or to mitigate withdrawal symptoms at home, such as kratom, ibogaine, and loperamide, all of which have potentially toxic effects. Treatment and recovery providers need to be knowledgeable of how patients self-treat opioid withdrawal, and to understand and manage the complications that arise from such practices. Additionally, patients may present with precipitated withdrawal from buprenorphine, naltrexone, or well-intended naloxone administration. These periods of intense withdrawal place patients at risk for medical complications and can jeopardize the early stages of recovery. Understanding the risks and optimizing management using opioid and non-opioid strategies can comfort patients and improve treatment engagement. This session is an interactive case-based workshop in which clinicians will discuss strategies to manage patients with atypical or unusually severe presentations related to opioid self-detoxification and precipitated withdrawal. Cases will illustrate the expected and unintended consequences related to the use of loperamide, kratom, and ibogaine as agents of self-detoxification. Attendees will develop approaches to diagnose and manage the complications of these so-called “alternative” detoxification agents, and learn to identify and treat the withdrawal that develops after regular use of kratom. We will also review the pathophysiology of precipitated withdrawal, discuss strategies to prevent this complication, and examine options to manage severe withdrawal. As there is currently no consensus on the best practices for treating atypical or complex opioid withdrawal, this session will offer an in-depth look at the benefits, risks, and knowledge gaps in rapid buprenorphine induction after naloxone- or naltrexone-precipitated withdrawal, and evaluate the use of other evidence-based agents such as opioid agonists, alpha-2 agonists, gabapentin, and atypical antipsychotics for patients with these multifaceted opioid withdrawal syndromes.  


    Learning Objectives:


    1.)  Recognize the toxic syndromes that result from strategies patients use to self-treat opioid withdrawal.

    2.)  Discuss the varied clinical presentation and management of patients with atypical or complex opioid withdrawal. 

    3.)  Identify methods to minimize the risk of and manage precipitated withdrawal from opioid antagonists or partial agonists.



    Aliana R. Steck

    MD

    Dr. Alaina Steck is a graduate of the Keck School of Medicine at the University of Southern California, did her residency training in Emergency Medicine at Boston Medical Center, and completed fellowship at the Emory University / Centers for Disease Control and Prevention Joint Fellowship in Medical Toxicology. She is board-certified in Emergency Medicine, Medical Toxicology, and Addiction Medicine, and practices all three clinical specialties at Grady Memorial Hospital in Atlanta, Georgia. She serves as an assitant medical director at the Georgia Poison Center and the medical director of the Grady Medication-Assisted Opioid Treatment clinic.

    ACCME Accredited with Commendation

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s).  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    ABPM Maintenance of Certification (MOC)

    The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 1.5 LLSA credits towards ABPM MOC Part II requirements.

    ABAM Transitional Maintenance of Certification (tMOC)

    This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Transitional Maintenance of Certification Program (tMOC) can apply a maximum of 1.5 AMA PRA Category 1 Credit(s)™ for completing this course.

    ABIM Maintenance of Certification (MOC)

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn 1.5 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

  • Enhancing Motivation, MAT Adherence & Retention with Routine Use of Contingency Management (1.5 CME)

    Product not yet rated Contains 4 Component(s), Includes Credits

    Earn 1.5 AMA PRA Category 1 Credit(s)™ while learning how to describe the foundation for enhanced treatment outcomes in SUD patients using contingency management from this conference recording from The ASAM 50th Annual Conference (2019).

    (1.5 CME) In this conference recording from the 2019 Annual Conference, you will learn that Contingency Management (CM) is the best-researched, most effective -- yet least utilized -- treatment innovation in addiction. After a half-century of research, clinicians still have numerous concerns: ethics (is it enabling to pay patients money?), resources (where will the money come from?), testing (frequent and visually witnessed drug testing?) & management (who will do the intricate accounting?). Technology can surmount each of these obstacles, with the added plus of patient engagement & relapse/dropout prediction. Providers will describe technology's potential for enhancing motivation, improving MAT adherence, & extending treatment retention. Data from thousands of patient events with several different technologic tools indicates that these approaches are feasible with many types of: Substance use disorders (from tobacco smoking to opioids) Subpopulations (from pregnant women to criminal justice-involved returning citizens to corporate executives) Providers (from counselors to case managers to recovery coaches), and Settings (from medical centers to recovery homes to national insurance companies). Finally, large data (e.g.,  < 90,000 financial transaction events from 1,400 patients) can generate imminent dropout and relapse indicators with good validity (e.g., 70% positive predictive value) that can be used to issue real-time alerts to providers to intervene -- even prior to a patient's return to drug use, allowing rapid treatment intensification without the need for repeat detoxification to address withdrawal. Impacts range from decreased drinking, to longer treatment retention to meaningful program completion (e.g., improving graduation rates from 67% to 87% within a justice-system involved long-term rehabilitation). Attendees will workshop how to achieve practical implementation within busy, oversubscribed and scarcely-resourced practices and treatment programs in the midst of an epidemic.


    Learning Objectives:

    1.) Explain the obstacles that have prevented wide-spread adoption of contingency management in routine care.

    2.) Describe the research foundation for enhancing treatment outcomes in patients with substance use disorders using contingency management. 

    3.) Analyze the utility of various new technologies that have been proposed and implemented to overcome the obstacles to adoption of contingency management.

    David Gastfriend

    MD, DFASAM

    David R. Gastfriend, MD, served on the faculty of Harvard Medical School for 25 years, most recently as Director of the Addiction Research Program at Massachusetts General Hospital (MGH). His studies of the Patient Placement Criteria published by the American Society of Addiction Medicine (ASAM) have been supported by the NIH's National Institute on Drug Abuse, the National Institute on Alcohol Abuse and Alcoholism, the U.S. Centers for Disease Control, U.S. state governments, managed care corporations, including Aetna Behavioral Healthcare, and foreign governments, including Belgium, Finland, Iceland, Israel, Norway, Switzerland, and the World Health Organization. The author of over 125 scientific publications, he has served on the Boards and Editorial Boards of a number of societies and journals, including ASAM and the International Society of Addiction Medicine (ISAM). He is co-editor of the leading book on treatment matching in the field, The ASAM Patient Placement Criteria for Substance-Related Disorders and editor of Addiction Treatment Matching. In addition to his role at RecoverySearch, Dr. Gastfriend is also Vice President for Scientific Communications at Alkermes, Inc. (NASDAQ: ALKS) where he is involved in research, education and scientific publication on extended-release naltrexone (VIVITROL®) and the company's efforts in the field of addiction treatment.

    ACCME Accredited with Commendation

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s).  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    ABPM Maintenance of Certification (MOC)

    The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 1.5 LLSA credits towards ABPM MOC Part II requirements.

    ABAM Transitional Maintenance of Certification (tMOC)

    This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Transitional Maintenance of Certification Program (tMOC) can apply a maximum of 1.5 AMA PRA Category 1 Credit(s)™ for completing this course.

    ABIM Maintenance of Certification (MOC)

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn 1.5 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

  • Opening Scientific Plenary & Distinguished Scientist Lecture (1.5 CME)

    Contains 4 Component(s), Includes Credits

    Earn 1.5 AMA PRA Category 1 Credit(s)™ while learning how to understand and mitigate risk factors leading up to drug use from this conference recording from The ASAM 50th Annual Conference (2019).

    (1.5 CME) In this conference recording from the 2019 Annual Conference, you will learn that:

    The Special ASAM 50th Annual Conference begins with an energizing Opening Scientific Plenary Session and highlights from the past 50 years. Moderated by ASAM President Kelly J. Clark, MD, MBA, DFAPA, DFASAM, distinguished presenters of the opening session will focus on incredible cutting-edge science in addiction medicine and a new paradigm of hope for prevention and treatment. Nora D. Volkow, MD Science Advances in the Prevention and Treatment of Opioid Addiction The misuse of and addiction to opioids"including prescription pain relievers, heroin, and synthetic opioids such as fentanyl"has resulted in a national crisis that we have not yet been able to revert. This presentation will highlight how NIH researchers are using scientific advances being made to turn the tide in the opioid crisis through the development of: new medications to treat pain; innovative drug abuse prevention strategies that can mitigate an individual’s vulnerability to addiction; and promising strategies that can successfully treat opioid use disorder and prevent and reverse overdose. Bankole Johnson Personalizing the Treatment for Alcohol Use Disorders This presentation will characterize the development of a genetic-based treatment for alcohol use disorders from animals to humans as well as prospects for regulatory approval. What is the genetic loading for alcohol use disorder? What is an inverted U-shaped dose curve? What is the frequency of the target genetic cohort for the treatment of alcohol use disorders? David & Nic Sheff A New Paradigm Facing America's Drug Use and Addiction Crises We're in crisis, but there's hope. The hope is a new paradigm for preventing and treating drug use and addiction in America. For prevention, we focus on drugs, but the key to prevention is a recognition of why people use them--understanding and mitigating risk factors. For treatment: We're at the beginning of a sea change as we reject failed efforts of the past -- ones based on the view that addiction is a choice -- and replace it with one based on the science of addiction medicine. We've a long way to go at a time we're losing more people under 50 from overdose than anything else. But we have a roadmap.
    ACCME Accredited with Commendation

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s).  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    ABPM Maintenance of Certification (MOC)

    The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 1.5 LLSA credits towards ABPM MOC Part II requirements.

    ABAM Transitional Maintenance of Certification (tMOC)

    This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Transitional Maintenance of Certification Program (tMOC) can apply a maximum of 1.5 AMA PRA Category 1 Credit(s)™ for completing this course.

    ABIM Maintenance of Certification (MOC)

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn 1.5 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

  • Designer Drugs Update 2019: Phenibut, Synthetic Opioids, & More (1.5 CME)

    Contains 4 Component(s), Includes Credits

    Earn 1.5 AMA PRA Category 1 Credit(s)™ while learning how to recognize clinical clues to intoxication with emerging designer drugs, and ways to differentiate from other drug use from this conference recording from The ASAM 50th Annual Conference (2019).

    (1.5 CME) In this conference recording from the 2019 Annual Conference, you will learn that/about:

    Learning Objectives:

    1.) Identify emerging designer drugs, including phenibut, synthetic opioids, and others.

    2.) Recognize clinical clues to intoxication with emerging designer drugs, and ways to differentiate from other drug use.

    3.) Discuss treatment of medical and psychiatric complications resulting from use of designer drugs.

    Patterns of drug abuse are constantly changing. This is particularly the case regarding new psychoactive substances or designer drugs, in which new variants are continually emerging with uptake especially among young adults. New synthetic designer drugs can be challenging to identify and treat effectively, especially serious medical and psychiatric complications. This is important for practitioners, as new designer drugs have resulted in multiple deaths, as well as other significant health consequences to users. This session will educate practitioners about several newer designer drugs regarding use trends along with psychotropic and health effects. Session description: This focus session will inform attendees with a discussion�"including clinical case examples�"that will focus on emerging designer drugs, including phenibut, synthetic opioids, and others. Use of these drugs has caused significant medical and psychiatric consequences, including multiple deaths, which has received recent media attention.  The presentation will be evidence-based and draw from existing medical literature, and will also include the panelists’ clinical experience with patients experiencing designer drug use and complications. The emphasis will be on clinical issues, especially recognition of intoxication, problems related to detection with urine drug testing, and treatment of medical and psychiatric complications. Attention will be given to specific populations that have been shown to be using these designer drugs. The presenters are experienced clinicians who have been involved in evaluation of patients using designer drugs. The presenters have also published about designer drugs in peer-reviewed journals. Attendees will be able to share their own experiences with patient use of designer drugs to enrich the discussion. Time will be allowed for questions to the panelists so that there will be significant interaction during this focus session. Conclusions: This focus session will provide attendees with evidence-based clinical knowledge to help identify and treat complications from newer designer drug use, especially those with life-threatening complications.  

    Michael F. Weaver

    MD, DFASAM

    Dr. Michael Weaver is Professor of Psychiatry and Medical Director of the Center for Neurobehavioral Research on Addiction at The University of Texas McGovern Medical School at Houston. He completed a Residency in Internal Medicine and a Clinical Research Fellowship in Addiction Medicine at Virginia Commonwealth University. He is involved in patient care, medical education, and research. Dr. Weaver has multiple publications in the field of addiction medicine. He treats patients at the Innovations Addiction Treatment Clinic at the Texas Medical Center in Houston, which provides medication-assisted treatment. He is the Sub-Board Chair for Addiction Medicine for the American Board of Preventive Medicine.  He is a member of the ASAM Publications Council and on the Editorial Board for the Journal of Addiction Medicine.

    ACCME Accredited with Commendation

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s).  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    ABPM Maintenance of Certification (MOC)

    The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 1.5 LLSA credits towards ABPM MOC Part II requirements.

    ABAM Transitional Maintenance of Certification (tMOC)

    This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Transitional Maintenance of Certification Program (tMOC) can apply a maximum of 1.5 AMA PRA Category 1 Credit(s)™ for completing this course.

    ABIM Maintenance of Certification (MOC)

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn 1.5 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

  • Big Ideas Plenary (1.5 CME)

    Product not yet rated Contains 4 Component(s), Includes Credits

    Earn 1.5 AMA PRA Category 1 Credit(s)™ while learning what ideas are shaping the future of addiction medicine from this conference recording from The ASAM 50th Annual Conference (2019).

    (1.5 CME) In this conference recording from the 2019 Annual Conference, you will learn:

    What big ideas are shaping the future of addiction medicine? Draw inspiration from ASAM award recipients and insight from national innovators during the Big Ideas Plenary Session. ASAM President Kelly J. Clark, MD, MBA, DFAPA, DFASAM, will recognize award recipients on-stage and with personalized video clips of individuals making major contributions to the field. She will also moderate an informal fireside chat with representatives from the National Institute of Drug Abuse (NIDA), the National Institute on Alcohol Abuse and Alcoholism (NIAAA), and the Office of the Surgeon General. Agency leaders will each give a five-minute presentation on one innovative big idea from their respective institutions. The session will conclude with stimulating questions and lively conversation.

    Nora Volkow, MD

    Director, National Institute on Drug Abuse, National Institutes of Health

    Nora D. Volkow, M.D., became Director of the National Institute on Drug Abuse (NIDA) at the National Institutes of Health in May 2003. Her work has been instrumental in demonstrating that drug addiction is a disease of the human brain. She pioneered the use of brain imaging to investigate the toxic effects and addictive properties of abusable drugs and has also made important contributions to the neurobiology of obesity, ADHD, and aging.

    Dr. Volkow was born in Mexico, earned her medical degree from the National University of Mexico, and carried out her psychiatric residency at New York University. Prior to her tenure at NIDA she held leadership positions at the Department of Energy's Brookhaven National Laboratory including Director of Nuclear Medicine, Chairman of the Medical Department, and Associate Director for Life Sciences. She was also a professor in the Department of Psychiatry and Associate Dean of the Medical School at the State University of New York (SUNY)-Stony Brook.

    Dr. Volkow has published more than 600 scientific articles and edited three books on neuroimaging for mental and addictive disorders. Among her many awards have been selection for membership in the Institute of Medicine, and the International Prize from the French Institute of Health and Medical Research. She was also named one of Time Magazine's “Top 100 People Who Shape our World", included as “One of the 20 People to Watch" by Newsweek magazine, and named “Innovator of the year" by U.S. News & World Report in 2000.

    ACCME Accredited with Commendation

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s).  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    ABPM Maintenance of Certification (MOC)

    The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 1.5 LLSA credits towards ABPM MOC Part II requirements.

    ABAM Transitional Maintenance of Certification (tMOC)

    This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Transitional Maintenance of Certification Program (tMOC) can apply a maximum of 1.5 AMA PRA Category 1 Credit(s)™ for completing this course.

    ABIM Maintenance of Certification (MOC)

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn 1.5 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

  • Harm Reduction in the Addiction Continuum: Not as Radical As One Thinks (1.5 CME)

    Product not yet rated Contains 4 Component(s), Includes Credits

    Earn 1.5 AMA PRA Category 1 Credit(s)™ while learning how harm reduction can be used in clinical practice from this conference recording from The ASAM 50th Annual Conference (2019).

    (1.5 CME) In this conference recording from the 2019 Annual Conference, you will learn:

    Learning Objectives:


    1.) Review the definition and background of harm reduction and demonstrate that it is congruent with the management of patients with other chronic relapsing illnesses.

    2.) Describe case examples of patients who benefit from low threshold or harm reduction care to keep them engaged, and to lower the risks associated with ongoing substance use.

    3.) Identify opportunities for integrating harm reduction into your own practice.

    The hallmark of addiction is loss of control and ongoing compulsive substance use despite negative consequences and is underscored by significant difficulty in executive functioning and organization.  As such, especially early on in care or at a time of relapse, highly structured treatment modalities and scheduling are unrealistic for many at best, and potentially lethal for others at worst.   If late or missed appointments result in longer waits or missed opportunities for care, or substance use results in discharge from care or referral to a higher level of care when the patient is either not able or ready to make such a change, the result can be no level of care. Despite prescription drug monitoring programs, misuse deterrent opioid formulations, expanded education efforts for safe pain prescribing and SUD screening and management, increased buprenorphine trainings and expanded waivers, the substance use disorder treatment gap remains and the opioid overdose epidemic continues to soar.  The landscape of the opioid epidemic has changed even more dramatically with fentanyl and carfentanyl, requiring more readily available care and flexible care models to help keep people engaged in care, while we work with them through the natural history of substance use disorder.  By partnering with patients in this manner, we help keep them alive, lower their risk of ongoing serious health complications or overdose, and increase their chances of continuing to engage in meaningful treatment; we collaborate with them in the practice of harm reduction. The session organizers will review harm reduction as patient centered care congruent with the practice of all medical specialties.    They will describe specific case examples of how harm reduction can be used in clinical practice, review flexible care models to engage patients with ambivalence or other competing life priorities, and explore ways to gain buy-in from colleagues in order to shift culture and increase comfort in providing harm reduction care within their continuum. The second half of the session will be spent in small groups where participants will review potential barriers to incorporating harm reduction into practice and explore how they would envision operationalizing and providing such care within their current practice.  

    Laura G. Kehoe

    MD, MPH, FASAM

    Dr. Kehoe is an Assistant Physician at Massachusetts General Hospital and an Assistant Professor of Medicine at Harvard Medical School and is board certified in both Internal Medicine and Addiction Medicine.  She attended Tufts University School of Medicine and Boston University School of Public Health and completed her residency in Internal Medicine at Massachusetts General Hospital.   At Massachusetts General Hospital, she is the Medical Director of the Substance Use Disorder Bridge Clinic, an immediate access, urgent care addiction program.   She is actively involved in medical student and resident education as an attending physician on the inpatient Addiction Consult Team (ACT), and she is the co-chair of the hospital-wide Substance Use Disorder Education Committee, where she works with other team members to expand evidence-based treatment of patients with addiction. 

    Outside of MGH, she was the Medical Director of Baycove Treatment Center for Opiate Addictions Methadone Maintenance program and she treats patients as part of a multidisciplinary addiction team at the supportive housing and outpatient non-profit, Right Turn.   Lastly, Dr. Kehoe is a founding member of W.A.T.E.R.town (Watertown Access to Treatment Education and Recovery), a community coalition working to expand prevention, intervention and treatment for people with substance use disorder in Watertown, MA.

    ACCME Accredited with Commendation

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s).  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    ABPM Maintenance of Certification (MOC)

    The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 1.5 LLSA credits towards ABPM MOC Part II requirements.

    ABAM Transitional Maintenance of Certification (tMOC)

    This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Transitional Maintenance of Certification Program (tMOC) can apply a maximum of 1.5 AMA PRA Category 1 Credit(s)™ for completing this course.

    ABIM Maintenance of Certification (MOC)

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn 1.5 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

  • Pharmacotherapy Studies to Prevent Opioid Relapse Following Jail Release: Lessons Learned (1.5 CME)

    Product not yet rated Contains 4 Component(s), Includes Credits

    Earn 1.5 AMA PRA Category 1 Credit(s)™ while learning about opioid addiction problems in jail from this conference recording from The ASAM 50th Annual Conference (2019).

    (1.5 CME) In this conference recording from the 2019 Annual Conference, you will learn:


    Opioid use disorder (OUD) in US jail populations is a major public health concern. Individuals with OUD who do not receive treatment during incarceration have high rates of relapse and are exposed to increased risk of overdose death upon release. Despite the proven effectiveness of methadone and extended release naltrexone treatment for OUD, these medications are rarely initiated prior to release from jail. The National Institute on Drug Abuse funded a cooperative study consisting of three randomized clinical trials to examine the effectiveness of pharmacotherapy initiated prior to release from jails in Albuquerque, NM, Baltimore, MD, and New York, NY. These studies randomly assigned opioid-addicted adults in jail to begin: methadone treatment with or without patient navigation, or an enhanced treatment as usual condition (in Baltimore, N=225); to extended release naltrexone with and without patient navigation, or enhanced treatment as usual (in Albuquerque, N=150); and, to extended release naltrexone or enhanced treatment as usual (in New York, N=255). This series of presentations will outline the scope of the opioid addiction problem in jails, the rationale and use of these medications in jails, challenges in implementing these approaches in jail and post-release, and medical and psychiatric co-morbidities in this patient population.  Main results to date will be presented, including: patient willingness to be treated, rates of study treatment retention after release, and community drug treatment outcomes. Audience discussion surrounding opioid treatment in criminal justice settings will be encouraged.

    Learning Objectives:


    1.) Participants will be able to list three challenges to implementing pharmacotherapy for opioid addiction in jails.
    2.) participants will be able to describe the benefits of providing methadone and extended release naltrexone prior to release from jail.
    3.) participants will be able to describe the role of patient navigation in linking patients to opioid addiction treatment across the jail to community treatment chasm.


    Robert P. Schwartz

    MD

    Dr. Schwartz is a psychiatrist and Medical Director of the Friends Research Institute. He is Co-Principal Investigator of the Mid-Atlantic Node of the National Institute on Drug Abuse (NIDA) Clinical Trials Network. He has studied pharmacotherapy for Opioid Use Disorder in the community and in jail and prison through numerous NIDA grant award and has over 150 scientific publications. Dr Schwartz is Associate Professor of Psychiatry and is the recipient of the Dole-Nyswander Award from the American Association for the Treatment of Opioid Dependence.

    Joshua D. Lee

    MD, MSc, FASAM

    Joshua D. Lee MD, MSc is an Associate Professor in the Departments of Population Health and Medicine at the NYU School of Medicine. He is board-certified in Internal Medicine and Addiction Medicine and is a physician at Bellevue Hospital Center, NYU Langone Medical Center, and in the NYC jails. He directs the NYU ABAM Fellowship in Addiction Medicine. His research focuses on novel and medication treatments for addiction among criminal justice and primary care populations.

    ACCME Accredited with Commendation

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s).  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    ABPM Maintenance of Certification (MOC)

    The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 1.5 LLSA credits towards ABPM MOC Part II requirements.

    ABAM Transitional Maintenance of Certification (tMOC)

    This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Transitional Maintenance of Certification Program (tMOC) can apply a maximum of 1.5 AMA PRA Category 1 Credit(s)™ for completing this course.

    ABIM Maintenance of Certification (MOC)

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn 1.5 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.